SCHEMBL323442

SCHEMBL323442

COc1cc2c(c(OC)c1)C=C[N]2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.39
CYP1A2 P05177 5/20 0.39
CYP3A4 P08684 4/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CYP1A1 P04798 3/20 0.33
CYP1B1 Q16678 3/20 0.33
HPGD P15428 2/20 0.33
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
RAD52 P43351 1/20 0.33
ERN1 O75460 1/20 0.33
LMNA P02545 1/20 0.33
CRHR1 P34998 1/20 0.32
PDE3B Q13370 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1091153 0.79 ALDH1A1 (0.36) ALDH1A1
SCHEMBL1091118 0.71 CA1 (0.41) ALDH1A1CYP3A4CA12CA1CA2
SCHEMBL322514 0.67 TRPA1 (0.39) ALDH1A1CYP1A2CYP3A4CA12CA1
SCHEMBL1091800 0.65 ALDH1A1 (0.37) ALDH1A1CYP3A4CA12CA1CA2
SCHEMBL27475405 0.65 CA12 (0.38) ALDH1A1CYP1A2CYP3A4CA12CA1
SCHEMBL1402596 0.65 ALDH1A1 (0.53) ALDH1A1CYP1A2CYP3A4CA12CA1
SCHEMBL1203850 0.65 ALDH1A1 (0.53) ALDH1A1CYP1A2CYP3A4CA12CA1
SCHEMBL28650387 0.64 MAPT (0.38) ALDH1A1CYP3A4USP2MAPK1
Difucol Hexamethyl Ether SCHEMBL505203 0.64 CYP1A2 (0.60) ALDH1A1CYP1A2CYP3A4CA12CA1
SCHEMBL6512469 0.63 ALDH1A1 (0.50) ALDH1A1CYP1A2CYP3A4CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-B1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2015-09-30 EP disclosed
US-8575158-B2 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators ACTELION PHARMACEUTICALS LTD. (CH) 2013-11-05 US disclosed
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 ALDH1A1 2057/4885CYP1A2 159/4885CYP3A4 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.